A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Study Overview

• Status: Completed
• Conditions: Axial Spondyloarthritis
• Intervention / Treatment: Drug: Ixekizumab; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 773
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Ciudad Autonoma de Buenos Aire, Argentina, C1428DZF
    • Consultorios Reumatológicos Pampa
  • San Miguel de Tucuman, Argentina, 4000
    • CIR Centro de Investigacions Reumatologicas
  • Buenos Aires
    • Ciudad de Buenos Aires, Buenos Aires, Argentina, C1430EGF
      • Clinica Adventista de Belgrano
    • Quilmes, Buenos Aires, Argentina, B1878DVC
      • Cer Instituto Medico
  • Santa Fe
    • Rosario, Santa Fe, Argentina, S2000CFJ
      • Centro de Enfermedades del Higado y Aparato Digestivo
  • Tucuman
    • San Miguel de Tucuman, Tucuman, Argentina, T4000AXL
      • Centro Medico Privado de Reumatologia
• Austria
  • Wien, Austria, 1060
    • KH der Barmherzigen Schwestern Wien BetriebsGesmbH
• Brazil
  • Goiás, Brazil, 74110-120
    • CIP - Centro Internacional de Pesquisa
  • Minas Gerais
    • Juiz de Fora, Minas Gerais, Brazil, 36010-570
      • CMiP - Centro Mineiro de Pesquisa
  • Paraná
    • Curitiba, Paraná, Brazil, 80440-080
      • EDUMED - Educação em Saúde Ltda.
  • RJ
    • Rio de Janeiro, RJ, Brazil, 22271-100
      • CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA
  • RS
    • Porto Alegre, RS, Brazil, 90035-903
      • Hospital de Clínicas de Porto Alegre
  • Rio Grande Do Sul
    • Porto Alegre, Rio Grande Do Sul, Brazil, 90540-000
      • LMK Serviços Médicos S/S
  • São Paulo
    • Sao Paulo, São Paulo, Brazil, 01228-200
      • Cpclin Centro de Pesquisas Clinicas
• Canada
  • Quebec, Canada, G1V 3M7
    • Group de recherche en maladies osseuses
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
      • University of Alberta Hospital
  • Newfoundland and Labrador
    • St. John's, Newfoundland and Labrador, Canada, A1C 5B8
      • St. Clare's Mercy Hospital
  • Quebec
    • Trois-Rivieres, Quebec, Canada, G8Z 1Y2
      • Centre De Recherche Musculo-Squelettique
• Czechia
  • Brno, Czechia, 611 41
    • Revmaclinic, s.r.o
  • Ostrava, Czechia, 703 00
    • Interni a revmatologicka ambulance, Inrea s.r.o.
  • Pardubice, Czechia, 530 02
    • Arthrohelp s.r.o
  • Praha 2, Czechia, 128 50
    • Revmatologicky ustav
  • Uherske Hradiste, Czechia, 686 01
    • Medical Plus, S.R.O.
• Finland
  • Helsinki, Finland, 00100
    • Terveystalo Kamppi
  • Helsinki, Finland, 00029
    • Helsinki University Hospital, HYKS
  • Hyvinkaa, Finland, 05800
    • Kiljava Medical Research
• France
  • Chambray-lès-Tours, France, 37170
    • Hôpital Trousseau, CHRU de Tours
  • Montpellier Cedex 5, France, 34295
    • Centre Hospitalier Universitaire Lapeyronie
  • Orleans CEDEX 2, France, 45067
    • Nouvel Hôpital Orléans La Source
• Germany
  • Berlin, Germany, 12203
    • Charite Universitatsmedizin Berlin
  • Hamburg, Germany, 20095
    • HRF Hamburger Rheuma Forschungszentrum
  • Mecklenburg-Vorpommern
    • Bad Doberan, Mecklenburg-Vorpommern, Germany, 18209
      • Rheumazentrum Prof. Neeck
  • Nordrhein-Westfalen
    • Herne, Nordrhein-Westfalen, Germany, 44649
      • Rheumazentrum Ruhrgebiet
• Hungary
  • Budapest, Hungary, 1027
    • Revita Reumatológiai Kft.
  • Veszprem, Hungary, 8200
    • Vital Medical Center
• Israel
  • Ashkelon, Israel, 7830604
    • Barzilai Medical Center
  • Haifa, Israel, 3109601
    • Rambam Medical Center
  • Petach Tikva, Israel, 4941492
    • Rabin Medical Center
  • Tel Aviv, Israel, 6423906
    • Tel Aviv Sourasky Medical Center
• Italy
  • Reggio Emilia, Italy, 42123
    • Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia
• Japan
  • Okayama, Japan, 700-8607
    • Japanese Red Cross Okayama Hospital
  • Osaka, Japan, 545-8586
    • Osaka City University Hospital
  • Osaka, Japan, 534-0021
    • Osaka City General Hospital
  • Yamagata, Japan, 990-9585
    • Yamagata University Hospital
  • Hokkaido
    • Sapporo, Hokkaido, Japan, 060-8648
      • Hokkaido University Hospital
  • Kagawa
    • Kita-gun, Kagawa, Japan, 761-0793
      • Kagawa University Hospital
  • Kochi
    • Nankoku, Kochi, Japan, 783-8505
      • Kochi Medical School Hospital
  • Mie
    • Kuwana, Mie, Japan, 511-0061
      • Kuwana City Medical Center
  • Nagasaki
    • Sasebo, Nagasaki, Japan, 857-1195
      • Sasebo Chuo Hospital
  • Osaka
    • Suita-shi, Osaka, Japan, 565 0871
      • Osaka University Hospital
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8431
      • Juntendo University Hospital
    • Chuo-Ku, Tokyo, Japan, 104 8560
      • St. Lukes International Hospital
• Korea, Republic of
  • Daejeon, Korea, Republic of, 35015
    • Chungnam National University Hospital
  • Seoul, Korea, Republic of, 03080
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 06273
    • Gangnam Severance Hospital
  • Seoul, Korea, Republic of, 05278
    • Kyunghee University Hospital at Gangdong
  • Seoul, Korea, Republic of, 04763
    • Hanyang University Medical Center
  • Seoul, Korea, Republic of, 05030
    • Konkuk University Hospital
  • Seoul, Korea, Republic of, 07061
    • Seoul Municipal Boramae Hospital
  • Korea
    • Seoul, Korea, Korea, Republic of, 06591
      • Seoul st. mary's hospital
    • Seoul, Korea, Korea, Republic of, 02447
      • Kyung Hee University Hospital
  • Seoul
    • Songpa-gu, Seoul, Korea, Republic of, 05505
      • Asan Medical Center
• Mexico
  • Chihuahua, Mexico, 31000
    • Investigación y Biomedicina de Chihuahua, SC
  • Baja California
    • Mexicali, Baja California, Mexico, 21200
      • Ctro Inv en Artritis y Osteoporosis SC
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44620
      • Unidad de Investigacion en Enfermedades Cronico Degenerative
    • Guadalajara, Jalisco, Mexico, 44650
      • Clinica en Investigación en Reumatologia y Obesidad S.C.
  • Nuevo Leon
    • Monterrey, Nuevo Leon, Mexico, 64460
      • Hospital Universitario de Monterrey
  • SLP
    • San Luis Potosi, SLP, Mexico, 78213
      • Centro de Alta Especialidad Reumatologia Inv del Potosi SC
  • Yucatan
    • Merida, Yucatan, Mexico, 97070
      • Medical Care and Research, S.A. de C.V.
• Netherlands
  • Amsterdam, Netherlands, 1105 AZ
    • Academisch Medisch Centrum
  • Sneek, Netherlands, 8601 ZK
    • Antonius Ziekenhuis
• Poland
  • Bialystok, Poland, 15-351
    • Nzoz Zdrowie Osteo-Medic
  • Bydgoszcz, Poland, 85-168
    • Szpital Uniwersytecki nr 2 im. dr J. Biziela
  • Elblag, Poland, 82-300
    • Centrum Kliniczno-Badawcze
  • Lodz, Poland, 90-558
    • Centrum Leczenia Osteoporozy Klinika Zdrowej Kosci
  • Nadarzyn, Poland, 05-830
    • Lecznica MAK-MED, NZOZ
  • Poznan, Poland, 61-397
    • Prywatna Praktyka Lekarska P. Hrycaj
  • Swidnik, Poland, 21-040
    • Lubelskie Centrum Diagnostyczne
  • Warszawa, Poland, 03-291
    • Centrum Medyczne AMED
  • Warszawa, Poland, 02-691
    • Reumatika Centrum Reumatologii
• Puerto Rico
  • San Juan, Puerto Rico, 00909
    • GCM Medical Group PSC
  • San Juan, Puerto Rico, 00918
    • Mindful Medical Research
  • San Juan, Puerto Rico, 00909
    • Latin Clinical Trial Center
• Romania
  • Bucuresti, Romania, 011172
    • Spitalul Clinic Sf Maria Bucuresti
  • Constanta, Romania, 900591
    • Sp Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta
• Russian Federation
  • Moscow, Russian Federation, 115522
    • V.A. Nasonova Research Institute of Rheumatology
  • Moscow, Russian Federation, 119049
    • City Clinical Hospital N1
  • Ryazan, Russian Federation, 390026
    • Ryazan Regional Clinincal Cardiology Dispensary
  • Saratov, Russian Federation, 410026
    • Saratov State Medical University
  • St. Petersburg, Russian Federation, 190068
    • Clinical Rheumatology Hospital # 25
  • Yaroslavl, Russian Federation, 150003
    • Clinical Hospital for Emergency Care
• Spain
  • Madrid, Spain, 28007
    • Hospital General Universitario Gregorio Maranon
  • Sevilla, Spain, 41010
    • Hospital Infanta Luisa
  • Barcelona
    • Sabadell, Barcelona, Spain, 08208
      • Centro de Salud Mental Parc Tauli
• Taiwan
  • Kaohsiung, Taiwan, 83301
    • Chang Gung Memorial Hospital - Kaohsiung
  • Taichung, Taiwan, 40447
    • China Medical University Hospital
  • Taichung City, Taiwan, 40201
    • Chung Shan Medical University Hospital
  • Taipei, Taiwan, 10002
    • National Taiwan University Hospital
  • Yongkang City, Taiwan, 71004
    • Chi-Mei Medical Center
• United Kingdom
  • Manchester
    • Wythenshawe, Manchester, United Kingdom, M23 9LT
      • Wythenshawe Hospital
  • Norfolk
    • Norwich, Norfolk, United Kingdom, NR4 7UY
      • Norfolk and Norwich Hospital
  • Staffordshire
    • Stoke on Trent, Staffordshire, United Kingdom, ST6 7AG
      • Haywood Hospital
  • West Midland
    • Solihull, West Midland, United Kingdom, B91 2JL
      • Solihull Hospital
  • West Midlands
    • Wolverhampton, West Midlands, United Kingdom, WV10 0QP
      • New Cross Hospital
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85032
      • Arizona Arthritis & Rheumatology Research
  • California
    • Huntington Beach, California, United States, 92648
      • Care Access Research - Huntington Beach
    • Palm Desert, California, United States, 92260
      • Desert Medical Advances
  • Colorado
    • Colorado Springs, Colorado, United States, 80920
      • Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
  • Connecticut
    • Danbury, Connecticut, United States, 06810
      • Clinical Research Center of CT/NY
  • Florida
    • Aventura, Florida, United States, 33180
      • Arthritis Rheumatic Disease Specialties
    • Sarasota, Florida, United States, 34239
      • Sarasota Arthritis Center
  • Georgia
    • Marietta, Georgia, United States, 30060
      • Marietta Rheumatology
  • Idaho
    • Idaho Falls, Idaho, United States, 83404
      • Institute of Arthritis Research
  • Kentucky
    • Elizabethtown, Kentucky, United States, 42701
      • Center for Arthritis & Osteoporosis
  • Maryland
    • Cumberland, Maryland, United States, 21502
      • Klein and Associates MD, PA
    • Hagerstown, Maryland, United States, 21740
      • Klein and Associates MD, PA
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Arthritis Consultants Inc.
  • Montana
    • Kalispell, Montana, United States, 59901
      • Glacier View Research Institute
  • Nebraska
    • Lincoln, Nebraska, United States, 68516
      • Physician Research Collaboration, LLC
  • North Carolina
    • Raleigh, North Carolina, United States, 27617
      • Shanahan Rheumatology & Immunotherapy, PLLC
    • Wilmington, North Carolina, United States, 28401
      • Carolina Arthritis Associates
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health and Science University
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Altoona Center for Clinical Research
  • South Carolina
    • Columbia, South Carolina, United States, 29204
      • Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
    • Summerville, South Carolina, United States, 29486
      • Articularis Healthcare d/b/a/ Low Country Rheumatology, PA
  • Texas
    • Houston, Texas, United States, 77030
      • Univ of Texas Health Science Center - Houston
  • Washington
    • Spokane, Washington, United States, 99204
      • Arthritis Northwest PLLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Have completed the final study visit in Study RHBV (NCT02696785), RHBW (NCT02696798), or RHBX (NCT02757352).

(Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor).

• Must agree to use a reliable method of birth control.

Exclusion Criteria:

• Have significant uncontrolled disorders or abnormal laboratory values that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered.
• Have a known hypersensitivity to ixekizumab or any component of this investigational product.
• Had investigational product permanently discontinued during a previous ixekizumab study.
• Had temporary investigational product interruption at any time during or at the final study visit of a previous ixekizumab study and, in the opinion of the investigator, restarting ixekizumab poses an unacceptable risk for the participant's participation in the study.
• Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol.
• Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ixekizumab (IXE) 80Q4W; Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).	Drug: Ixekizumab; Administered SC; Other Names: LY2439821
Experimental: Ixekizumab (IXE) 80Q2W; Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).	Drug: Ixekizumab; Administered SC; Other Names: LY2439821
Placebo Comparator: Placebo; Participants received subcutaneous dose of placebo.	Drug: Placebo; Administered SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)	A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS >3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.	Week 64

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who do Not Experience a Flare	A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS >3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.	Week 64
Change From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)	The mSASSS is a four-point scoring system for lateral radiographs of the lumbar and cervical spine and has been shown to reliably track disease progression over time, where: 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge. By the scoring system of mSASSS of the spinal x-rays, a total of 24 sites were scored on the lateral cervical and lumbar spine: the anterior corners of the vertebrae from lower border of C2 to upper border T1 (inclusive), and from lower border of T12 to upper border of S1 (inclusive). Each corner was scored from 0 to 3, resulting in a range from 0 [no change] to 72 [progression].	Baseline, 2 Years
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response	ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 & Q6 (mean of intensity & duration of stiffness): Score ranges from "0" (none) and "10" (very severe).	Week 64
Percentage of Participants Achieving an ASAS40 Response	ASAS40 is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 & Q6 (mean of intensity & duration of stiffness): Score ranges from "0" (none) and "10" (very severe).	Week 64
Percentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units	ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness +0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.	Week 64
Percentage of Participants With Inactive Disease on the ASDAS (<1.3 Units)	ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.	Week 64
Change From Baseline in the Individual Components of the ASAS Criteria	Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on Q5 & Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity & duration of stiffness): Score ranges from "0" (none) and "10" (very severe). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response	The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.	Week 64
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)	High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)	BASMI is a combined index comprising of the following 5 clinical measurements of spinal mobility in participants with radiographic axial spondyloarthritis (rad-axSpA).; Lateral Spinal Flexion; Tragus-to-wall distance; Lumbar Flexion (modified Schober); Maximal intermalleolar distance and; Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the participant's limitation of movement due to their AS. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Chest Expansion in Centimeters	Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While participants have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Occiput to Wall Distance	The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)	The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score	The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints	The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints	The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Percentage of Participants With Anterior Uveitis or Uveitis Flares	Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.	Week 64
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score	The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)	The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score	The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in SF-36 Mental Component Summary (MCS) Score	The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in ASAS Health Index (ASAS HI)	The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the participant needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score	The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0- to 100-mm visual analog scale (VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores	The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA participant population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)	The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.	Baseline, Week 64
Percentage of Participants With No New Syndesmophyte Formation	Percentage of participants with no new syndesmophyte formation was measured using the average of 2 selected readers of 3 readers.	Week 56
Percentage of Participants With Anti-Ixekizumab Antibodies	A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a >= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of >= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.	Baseline, Week 64

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Publications and helpful links

General Publications

• Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open. 2022 Jul;8(2):e002165. doi: 10.1136/rmdopen-2021-002165.

Helpful Links

• A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis (COAST-Y)

Study record dates

Study Major Dates

• Study Start (Actual): May 9, 2017
• Primary Completion (Actual): May 26, 2020
• Study Completion (Actual): May 27, 2021

Study Registration Dates

• First Submitted: April 3, 2017
• First Submitted That Met QC Criteria: April 21, 2017
• First Posted (Actual): April 26, 2017

Study Record Updates

• Last Update Posted (Actual): June 13, 2022
• Last Update Submitted That Met QC Criteria: May 12, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Joint Diseases; Musculoskeletal Diseases; Arthritis; Spinal Diseases; Bone Diseases; Bone Diseases, Infectious; Spondylitis; Spondylarthritis; Dermatologic Agents; Ixekizumab
• Other Study ID Numbers: 16181; I1F-MC-RHBY (Other Identifier: Eli Lilly and Company); 2016-002634-69 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
• IPD Sharing Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
• IPD Sharing Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No